OrthoPediatrics Corp. (NASDAQ:KIDS) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on OrthoPediatrics, with nine buy ratings, one hold and one sell among 11 firms. The average 12-month price target is $26.44, including recent targets of $25 from Piper Sandler and $29 from BTIG Research.
• The company’s latest quarterly results exceeded expectations, reporting an adjusted loss of $0.26 per share versus the $0.30 expected loss and revenue of $70.51 million versus the $68.21 million consensus estimate. Analysts forecast a full-year loss of $1.14 per share.
• Insiders have been selling shares: insiders sold 2.1 million shares worth about $46.7 million over the past 90 days, while institutional investors own 69.05% of the stock.

OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eleven research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $26.4444.

A number of equities research analysts recently commented on the company. Piper Sandler reiterated an "overweight" rating and issued a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Weiss Ratings upgraded OrthoPediatrics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, August 5th. BTIG Research reaffirmed a "buy" rating and issued a $29.00 price objective on shares of OrthoPediatrics in a research note on Monday, September 14th. Truist Financial set a $22.00 price objective on OrthoPediatrics in a report on Wednesday, August 5th. Finally, TD Cowen reiterated a "buy" rating on shares of OrthoPediatrics in a research report on Monday, June 15th.

OrthoPediatrics Stock Performance

KIDS opened at $21.82 on Friday. The stock has a market capitalization of $569.72 million, a price-to-earnings ratio of -12.99 and a beta of 0.99. The company has a fifty day moving average of $22.25 and a 200 day moving average of $19.22. OrthoPediatrics has a fifty-two week low of $14.42 and a fifty-two week high of $26.74. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. The business had revenue of $70.51 million for the quarter, compared to analysts' expectations of $68.21 million. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. As a group, sell-side analysts forecast that OrthoPediatrics will post -1.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In other OrthoPediatrics news, Director David R. Pelizzon sold 302,369 shares of OrthoPediatrics stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the transaction, the director directly owned 6,201,764 shares of the company's stock, valued at $130,299,061.64. This trade represents a 4.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Jennifer N. Pritzker sold 302,369 shares of the business's stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the completion of the sale, the insider owned 6,201,764 shares in the company, valued at approximately $130,299,061.64. This trade represents a 4.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 2,100,000 shares of company stock worth $46,747,931. Insiders own 32.50% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in OrthoPediatrics during the second quarter worth approximately $24,347,000. Granahan Investment Management LLC raised its position in OrthoPediatrics by 35.1% during the first quarter. Granahan Investment Management LLC now owns 896,741 shares of the company's stock valued at $14,231,000 after purchasing an additional 232,760 shares during the period. Wasatch Advisors LP lifted its stake in shares of OrthoPediatrics by 56.6% in the 2nd quarter. Wasatch Advisors LP now owns 515,677 shares of the company's stock valued at $9,865,000 after purchasing an additional 186,357 shares during the last quarter. Roubaix Capital LLC lifted its stake in shares of OrthoPediatrics by 23.8% in the 1st quarter. Roubaix Capital LLC now owns 290,047 shares of the company's stock valued at $4,603,000 after purchasing an additional 55,724 shares during the last quarter. Finally, AIGH Capital Management LLC purchased a new position in shares of OrthoPediatrics in the 2nd quarter worth approximately $5,161,000. Institutional investors own 69.05% of the company's stock.

About OrthoPediatrics

OrthoPediatrics Corp. NASDAQ: KIDS develops, manufactures and sells orthopedic products designed specifically for children. The company focuses on addressing the distinct anatomical and clinical needs of pediatric patients, offering implants, instruments and related technologies for orthopedic surgery.

Its product portfolio includes solutions for pediatric trauma and deformity correction, scoliosis and spinal disorders, sports medicine, limb lengthening and reconstruction, and neuromuscular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.